about
Three-year multicenter surveillance of community-acquired Listeria monocytogenes meningitis in adults.Risk factors for fluconazole-resistant candidemia.Left-sided infective endocarditis in patients with liver cirrhosis.Proteomics-driven design of a multiplex bead-based platform to assess natural IgG antibodies to pneumococcal protein antigens in children.Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study.Global impact of an educational antimicrobial stewardship programme on prescribing practice in a tertiary hospital centre.Superinfection during treatment of nosocomial infections with tigecycline.Genetic variants of the MBL2 gene are associated with mortality in pneumococcal sepsis.Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections.A pragmatic approach for mortality prediction after surgery in infective endocarditis: Optimizing and refining EuroSCORE.[Invasive fungal infection in critically ill patients].Alternative statistical methods and their application to research in intensive care setting.Time to positivity of blood culture association with clinical presentation, prognosis and ESBL-production in Escherichia coli bacteremia.Rationale and design of DiPPI: A randomized controlled trial to evaluate the safety and effectiveness of progressive hemodialysis in incident patientsMore about the safety of tigecycline for the treatment of infectious diseases: the role of superinfection ratesIHDIP: a controlled randomized trial to assess the security and effectiveness of the incremental hemodialysis in incident patientsDeterminants of outcome in patients with bacteraemic pneumococcal pneumonia: Importance of early adequate treatmentSurgical treatment for infective endocarditis in elderly patientsRifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulationMeasure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatmentImplementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antiviralsLeft-sided infective endocarditis caused by Streptococcus agalactiae: rare and serious
P50
Q33743696-C8A67A62-6661-45E3-A7E0-3E3524AAE2C3Q39934814-1184B098-7AF2-4024-9E45-EAB61E34A7F9Q40980929-45E20F5A-169F-4279-BBAB-1671D3A7F514Q41133000-93E5FB18-12AA-4312-84DA-210C7AA957FAQ42264003-45753264-B8D2-40E3-B61D-F5D888793ED0Q42269983-FD35D1E2-8F7F-4723-A8D3-DE7FDC0CB2B2Q43062001-E6300B50-A867-43FE-B30F-2F2340F5F958Q43647038-F5321466-15C6-49D6-9D65-D10B97236CF6Q44830700-B8A40C21-85DE-4A63-9935-FCC5F1E169A5Q50167807-EBC0AAA6-403E-44CF-9332-E242F86B0970Q51172552-380001E7-02D2-431E-BAE6-0C53C77BF0B6Q52372036-5173094C-B440-4BC8-A1EB-783BA568AFF6Q53672275-B8D8B413-9CDB-4511-8C14-F0D291E7B9B5Q57812771-35D18C78-B46A-4B76-9BF6-00BC8C4923C5Q57901552-DCB16D1C-079E-40AC-9E5E-2654AB77D4FCQ60913145-21305808-1ACC-4E6B-94EE-29F5F121113DQ64131263-F6236DE7-4A7E-4016-AF82-AAE12F8BD185Q84378053-6A4C08CC-3348-441B-96AB-FCD974E09A10Q84395395-789E211D-B6FE-4C22-81E5-B98F4B20B632Q90935271-7B9921C1-B611-46A0-958E-A0F837DAC8FCQ91559792-D548DB5A-AD47-46EE-85D9-85D29395D54BQ93085878-267646F2-23A8-4950-96A9-6C85CD232D7C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Emilio García-Cabrera
@ast
Emilio García-Cabrera
@en
Emilio García-Cabrera
@es
Emilio García-Cabrera
@nl
type
label
Emilio García-Cabrera
@ast
Emilio García-Cabrera
@en
Emilio García-Cabrera
@es
Emilio García-Cabrera
@nl
prefLabel
Emilio García-Cabrera
@ast
Emilio García-Cabrera
@en
Emilio García-Cabrera
@es
Emilio García-Cabrera
@nl
P106
P108
P21
P31
P496
0000-0002-5529-6035